FDA Approved Indications for this Orphan Drug:

Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients

FDA Marketing Approval issued as of:

Orphan Drug exclusivity ends on:
Company Making and Marketing this drug:
AbbVie, Inc.

FDA Designation Date:

FDA Drug Designation:
Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis